Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) reported Q1 2026 PEMGARDA net product revenue of $13.7 million, up 22% from Q1 2025. Cash and equivalents were $184.2 million plus ~$20 million raised via ATM in April. R&D and SG&A rose sharply, driving a $41.4 million net loss, while pivotal VYD2311 DECLARATION data are now expected in Q3 2026. The company advanced VYD2311 programs, received multiple FDA interactions, and expanded its pipeline with measles candidate VMS063 and RSV candidate VBY329.
Invivyd (Nasdaq: IVVD) reported new analysis of early systemic side effects comparing COVID-19 monoclonal antibody adintrevimab with mRNA and protein vaccines. In the EVADE trial, Grade 2/3 systemic adverse events in the first seven days were 2% for monoclonal antibody versus 1% for placebo, compared with 91.6% for mRNA and 83.6% for protein vaccine in Sanofi’s COMPARE study. The MedRxiv preprint also models total symptom days from both reactogenicity and breakthrough infections. Invivyd plans the LIBERTY head-to-head trial evaluating systemic symptoms after mRNA vaccination versus low-dose VYD2311.
Invivyd (Nasdaq: IVVD) will host a webcast and conference call on May 14, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results and provide a corporate update. A replay will be available on the company investor website about two hours after the call.
Analysts may register to participate in the Q&A; attendees are advised to join 15 minutes early.
Invivyd (Nasdaq: IVVD) announced on May 1, 2026 the grant of inducement stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan.
The company granted options to 17 non-executive employees for an aggregate of 731,000 shares, at a per‑share exercise price of $1.52 (closing price on the grant date). Each option vests over four years (25% after one year, then monthly) and has a 10‑year term, subject to the plan and continued service.
Invivyd (Nasdaq: IVVD) announced Chairman Marc Elia will speak at the POLITICO Health Care Summit on April 21, 2026 from 11:30 AM–12:00 PM ET. The session will discuss viral disease prevention and the role of monoclonal antibodies in advancing public health. The event will be live streamed 9:00 AM–1:00 PM ET.
Invivyd (Nasdaq: IVVD) reported a DECLARATION Phase 3 sample-size re-estimation that upsizes the trial by ~500 subjects and shifts expected top-line timing modestly to Q3 2026. The company aligned with the FDA on an initial pediatric study plan and advanced VMS063, a potent measles monoclonal antibody, toward IND-enabling work with target IND readiness in late 2026.
VMS063 shows low ng/mL and high-pg/mL neutralization across circulating measles lineages, is half-life extended, and targets a conserved measles F protein epitope.
Invivyd (Nasdaq: IVVD) launched a national education campaign, Antibodies for Any Body, in partnership with skier Lindsey Vonn on April 7, 2026. The campaign debut includes AntibodiesforAnyBody.com and an interactive Wellness Assessment to explain antibodies and lifestyle links to immune health.
The site offers accessible resources about antibody function and how sleep, nutrition, and activity may support immune protection; visitors are encouraged to consult their doctor about personalized habits.
Invivyd (Nasdaq: IVVD) announced inducement option grants made April 1, 2026, to 16 newly hired non-executive employees totaling 1,083,750 options under the Invivyd 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry a per-share exercise price of $1.33 (closing price on the grant date), vest over four years with 25% after one year and monthly vesting thereafter, and have a 10-year term, subject to plan terms and continuous service.
Invivyd (Nasdaq: IVVD) announced that Chief Scientific Officer Robert Allen, Ph.D. presented at the World Vaccine Congress Washington on March 30, 2026.
His talk, titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving Viral Threats,” addressed monoclonal antibody scalability, access, economics, and strategies to manage virus variation, and highlighted Invivyd’s bespoke platform for vulnerable populations.
Invivyd (Nasdaq: IVVD) reported full-year 2025 net product revenue for PEMGARDA of $53.4M and Q4 2025 PEMGARDA revenue of $17.2M (Q4 YoY +25%). Cash and cash equivalents were $226.7M at year-end after >$200M raised in 2H 2025. DECLARATION Phase 3 enrollment is complete; top-line VYD2311 data expected mid-2026. FDA granted Fast Track for VYD2311 in Dec 2025. R&D expense fell to $38.3M and net loss narrowed to $52.5M for 2025.